Incyte Corporation (0J9P.L)
USD 58.02
(-0.72%)
USD 58.02
(-0.72%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 919.42 Million USD | 43.26% |
| 2022 | 599.63 Million USD | 3.33% |
| 2021 | 630.19 Million USD | 381.53% |
| 2020 | -178.23 Million USD | -145.81% |
| 2019 | 475.65 Million USD | 153.2% |
| 2018 | 209.83 Million USD | 185.64% |
| 2017 | -253.21 Million USD | -230.99% |
| 2016 | 204.57 Million USD | 188.94% |
| 2015 | 98.04 Million USD | 4071.11% |
| 2014 | 39.95 Million USD | 90.16% |
| 2013 | -14.98 Million USD | -872.91% |
| 2012 | 31.89 Million USD | 101.34% |
| 2011 | -115.73 Million USD | -893.83% |
| 2010 | 35.96 Million USD | 118.08% |
| 2009 | -123.07 Million USD | 31.89% |
| 2008 | -146.21 Million USD | -101.37% |
| 2007 | -72.31 Million USD | 2.1% |
| 2006 | -76.86 Million USD | 20.12% |
| 2005 | -92.59 Million USD | 30.74% |
| 2004 | -132.05 Million USD | -175.7% |
| 2003 | -149.29 Million USD | -30.86% |
| 2002 | -110.51 Million USD | -131.39% |
| 2001 | -17.03 Million USD | 548.0% |
| 2000 | -27.74 Million USD | -901.97% |
| 1999 | -2.3 Million USD | -90.91% |
| 1998 | 30 Million USD | 159.29% |
| 1997 | 14 Million USD | 976.92% |
| 1996 | -2.4 Million USD | 113.54% |
| 1995 | -8.1 Million USD | 19.33% |
| 1994 | -11.2 Million USD | -153.19% |
| 1993 | -4.5 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 179.81 Million USD | 148.99% |
| 2024 Q1 | 158.13 Million USD | -61.11% |
| 2024 Q2 | -455.18 Million USD | -421.59% |
| 2023 Q3 | 260.65 Million USD | -1.69% |
| 2023 FY | - USD | 43.26% |
| 2023 Q4 | 274.52 Million USD | 5.32% |
| 2023 Q1 | 63.83 Million USD | -47.27% |
| 2023 Q2 | 265.11 Million USD | 315.29% |
| 2022 Q1 | 124.18 Million USD | 5.13% |
| 2022 FY | - USD | 3.33% |
| 2022 Q4 | 121.07 Million USD | -16.32% |
| 2022 Q3 | 144.68 Million USD | -43.98% |
| 2022 Q2 | 258.26 Million USD | 107.97% |
| 2021 Q2 | 164.31 Million USD | 59.66% |
| 2021 Q3 | 254.95 Million USD | 55.16% |
| 2021 Q4 | 118.12 Million USD | -53.67% |
| 2021 FY | - USD | 381.53% |
| 2021 Q1 | 102.91 Million USD | -40.38% |
| 2020 Q3 | 30.3 Million USD | -88.08% |
| 2020 Q1 | -635.61 Million USD | -657.67% |
| 2020 Q2 | 254.23 Million USD | 140.0% |
| 2020 FY | - USD | -145.81% |
| 2020 Q4 | 172.63 Million USD | 469.73% |
| 2019 Q2 | 133.65 Million USD | 48.32% |
| 2019 Q1 | 90.11 Million USD | -10.53% |
| 2019 FY | - USD | 153.2% |
| 2019 Q3 | 149.55 Million USD | 11.9% |
| 2019 Q4 | 113.97 Million USD | -23.79% |
| 2018 Q3 | 59.86 Million USD | -45.5% |
| 2018 Q4 | 100.71 Million USD | 68.24% |
| 2018 Q1 | -42.53 Million USD | 63.44% |
| 2018 FY | - USD | 185.64% |
| 2018 Q2 | 109.85 Million USD | 358.24% |
| 2017 Q2 | 30.75 Million USD | 128.03% |
| 2017 FY | - USD | -230.99% |
| 2017 Q1 | -109.71 Million USD | -320.26% |
| 2017 Q3 | 16.11 Million USD | -47.61% |
| 2017 Q4 | -116.35 Million USD | -822.25% |
| 2016 Q3 | 48.44 Million USD | -20.39% |
| 2016 Q2 | 60.84 Million USD | 25.23% |
| 2016 FY | - USD | 188.94% |
| 2016 Q1 | 48.58 Million USD | -26.79% |
| 2016 Q4 | 49.81 Million USD | 2.83% |
| 2015 Q4 | 66.36 Million USD | 370.6% |
| 2015 Q2 | 5.01 Million USD | -23.19% |
| 2015 FY | - USD | 4071.11% |
| 2015 Q3 | 14.1 Million USD | 181.16% |
| 2015 Q1 | 6.53 Million USD | 126.45% |
| 2014 Q1 | -22.2 Million USD | -41.89% |
| 2014 Q3 | 80.69 Million USD | 614.04% |
| 2014 Q2 | -15.69 Million USD | 29.28% |
| 2014 Q4 | -24.68 Million USD | -130.59% |
| 2014 FY | - USD | 90.16% |
| 2013 Q4 | -15.64 Million USD | -90.11% |
| 2013 Q2 | 25.61 Million USD | 567.81% |
| 2013 Q1 | 3.83 Million USD | -87.47% |
| 2013 FY | - USD | -872.91% |
| 2013 Q3 | -8.23 Million USD | -132.13% |
| 2012 Q2 | 15.53 Million USD | 157.74% |
| 2012 Q4 | 30.62 Million USD | 1308.09% |
| 2012 Q3 | -2.53 Million USD | -116.32% |
| 2012 Q1 | -26.9 Million USD | 27.97% |
| 2012 FY | - USD | 101.34% |
| 2011 Q1 | -9.32 Million USD | -117.73% |
| 2011 FY | - USD | -893.83% |
| 2011 Q4 | -37.34 Million USD | -6.13% |
| 2011 Q3 | -35.18 Million USD | -2.48% |
| 2011 Q2 | -34.33 Million USD | -268.28% |
| 2010 FY | - USD | 118.08% |
| 2010 Q4 | 52.57 Million USD | 419.3% |
| 2010 Q3 | -16.46 Million USD | -184.4% |
| 2010 Q2 | 19.5 Million USD | 247.36% |
| 2010 Q1 | -13.23 Million USD | -1964.65% |
| 2009 Q4 | 710 Thousand USD | 103.24% |
| 2009 FY | - USD | 31.89% |
| 2009 Q1 | -31.73 Million USD | 16.14% |
| 2009 Q2 | -32.73 Million USD | -3.15% |
| 2009 Q3 | -21.92 Million USD | 33.04% |
| 2008 Q1 | -32.59 Million USD | -38.52% |
| 2008 Q4 | -37.84 Million USD | -2.99% |
| 2008 FY | - USD | -101.37% |
| 2008 Q2 | -38.34 Million USD | -17.67% |
| 2008 Q3 | -36.74 Million USD | 4.19% |
| 2007 Q1 | -16.87 Million USD | 38.27% |
| 2007 Q2 | -13.07 Million USD | 22.51% |
| 2007 Q3 | -19.25 Million USD | -47.29% |
| 2007 Q4 | -23.52 Million USD | -22.2% |
| 2007 FY | - USD | 2.1% |
| 2006 Q2 | -15.01 Million USD | 26.37% |
| 2006 Q4 | -27.32 Million USD | -89.4% |
| 2006 Q3 | -14.42 Million USD | 3.91% |
| 2006 Q1 | -20.39 Million USD | 18.1% |
| 2006 FY | - USD | 20.12% |
| 2005 Q1 | -16.01 Million USD | 48.64% |
| 2005 Q4 | -24.9 Million USD | 1.44% |
| 2005 Q2 | -26.36 Million USD | -64.64% |
| 2005 Q3 | -25.26 Million USD | 4.17% |
| 2005 FY | - USD | 30.74% |
| 2004 FY | - USD | -175.7% |
| 2004 Q1 | -30.05 Million USD | -61.21% |
| 2004 Q2 | -57.26 Million USD | -90.55% |
| 2004 Q3 | -15.75 Million USD | 72.49% |
| 2004 Q4 | -31.18 Million USD | -97.91% |
| 2003 Q2 | -22.04 Million USD | -438.4% |
| 2003 Q4 | -34.2 Million USD | -32.48% |
| 2003 Q3 | -30.17 Million USD | 35.64% |
| 2003 Q1 | -54.27 Million USD | -75.78% |
| 2003 FY | - USD | -30.86% |
| 2002 Q4 | -12.42 Million USD | 183.35% |
| 2002 Q2 | -18.35 Million USD | -49.96% |
| 2002 FY | - USD | -131.39% |
| 2002 Q3 | -31.85 Million USD | -74.86% |
| 2002 Q1 | -12.06 Million USD | -109.81% |
| 2001 Q3 | 2.42 Million USD | 233.22% |
| 2001 Q2 | -5.1 Million USD | -256.56% |
| 2001 FY | - USD | 548.0% |
| 2001 Q4 | -5.55 Million USD | 1244.82% |
| 2001 Q1 | 3.8 Million USD | 152.99% |
| 2000 Q3 | -6.11 Million USD | -2.26% |
| 2000 Q2 | -5.97 Million USD | 0.45% |
| 2000 FY | - USD | -901.97% |
| 2000 Q1 | -7.28 Million USD | -528.86% |
| 2000 Q4 | -8.37 Million USD | -36.98% |
| 1999 Q2 | -1.3 Million USD | -148.48% |
| 1999 Q3 | -4.58 Million USD | -68.75% |
| 1999 Q4 | 200 Thousand USD | 151.85% |
| 1999 Q1 | 3.43 Million USD | -42.11% |
| 1999 FY | - USD | -90.91% |
| 1998 Q4 | 6.6 Million USD | -65.45% |
| 1998 Q2 | 8.3 Million USD | -16.67% |
| 1998 FY | - USD | 159.29% |
| 1998 Q1 | 7.8 Million USD | 56.0% |
| 1998 Q3 | 7.3 Million USD | 153.85% |
| 1997 Q3 | 3.6 Million USD | -2.94% |
| 1997 FY | - USD | 976.92% |
| 1997 Q4 | 6.5 Million USD | 51.52% |
| 1997 Q1 | 2.8 Million USD | 76.92% |
| 1997 Q2 | 3.1 Million USD | 47.83% |
| 1996 Q1 | -1.8 Million USD | -25.0% |
| 1996 Q3 | 1.3 Million USD | 360.0% |
| 1996 FY | - USD | 113.54% |
| 1996 Q4 | 2 Million USD | -66.67% |
| 1996 Q2 | -900 Thousand USD | 40.0% |
| 1995 Q3 | -2.4 Million USD | 7.14% |
| 1995 Q2 | -2.5 Million USD | -33.33% |
| 1995 Q4 | -1.6 Million USD | 23.08% |
| 1995 Q1 | -1.8 Million USD | 53.33% |
| 1995 FY | - USD | 19.33% |
| 1994 Q1 | -2 Million USD | -66.67% |
| 1994 Q2 | -2.2 Million USD | -10.0% |
| 1994 FY | - USD | -153.19% |
| 1994 Q4 | -4 Million USD | -50.0% |
| 1994 Q3 | -2.9 Million USD | -36.36% |
| 1993 FY | - USD | 0.0% |
| 1993 Q3 | -1.1 Million USD | 0.0% |
| 1993 Q4 | -1.2 Million USD | -9.09% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| uniQure N.V. | -253.1 Million USD | 463.266% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 1918.053% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 1144.98% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 45.174% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 366.142% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 503.043% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 1098.519% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 1749.017% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 445.653% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 508.65% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -196.318% |
| bluebird bio, Inc. | -167.16 Million USD | 650.024% |
| Blueprint Medicines Corporation | -474.61 Million USD | 293.722% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 881.493% |
| Imunon, Inc. | -20.78 Million USD | 4524.087% |
| Adicet Bio, Inc. | -136.53 Million USD | 773.399% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -748.774% |
| Dynavax Technologies Corporation | 9.66 Million USD | -9411.959% |
| Editas Medicine, Inc. | -163.11 Million USD | 663.66% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 281.956% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 712.51% |
| Exelixis, Inc. | 196.6 Million USD | -367.659% |
| FibroGen, Inc. | -261.4 Million USD | 451.725% |
| Geron Corporation | -174.78 Million USD | 626.042% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -103.437% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 985.835% |
| Illumina, Inc. | -608 Million USD | 251.221% |
| Insmed Incorporated | -654.73 Million USD | 240.426% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 281.592% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 499.733% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 304.766% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 71.762% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 2648.157% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 21.015% |
| Evolus, Inc. | -41.81 Million USD | 2299.058% |
| Myriad Genetics, Inc. | -67.8 Million USD | 1456.086% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | -120.963% |
| OPKO Health, Inc. | -65.51 Million USD | 1503.361% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 309.343% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -835.688% |
| Verastem, Inc. | -83.16 Million USD | 1205.531% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 108.152% |
| Waters Corporation | 1.02 Billion USD | 10.059% |
| Zoetis Inc. | 3.68 Billion USD | 75.049% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 80.035% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 91.487% |
| Biogen Inc. | 2.37 Billion USD | 61.32% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 1151.65% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 80.245% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 2169.069% |
| Homology Medicines, Inc. | -47.75 Million USD | 2025.258% |
| Nektar Therapeutics | -243.1 Million USD | 478.198% |
| TG Therapeutics, Inc. | 26.1 Million USD | -3422.705% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 1011.885% |
| Perrigo Company plc | 646.2 Million USD | -42.282% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 2566.073% |